Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: The axtell regimen

Annals of Oncology

Volumn 23, Issue 3, 2012, Pages 785-790

  Verschraegen, C F ^a   Arias pulido, H ^a   Lee, S J ^a   Movva, S ^a   Cerilli, L A ^a   Eberhardt, S ^a   Schmit, B ^a   Quinn, R ^a   Muller, C Y ^a   Rabinowitz, I ^a   Purdy, M ^b   Snyder, D ^b   Bocklage, T ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b New Mexico Cancer Care Alliance ^*  (United States)

Author keywords

Bevacizumab; Docetaxel; Drug administration schedule; Gemcitabine; Soft tissue sarcomas

Indexed keywords

BEVACIZUMAB; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADENOSARCOMA; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANGIOSARCOMA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER TISSUE; CHILL; CHONDROSARCOMA; CLINICAL ARTICLE; COHORT ANALYSIS; DIARRHEA; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIPHORA; EPISTAXIS; EYE IRRITATION; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMANGIOPERICYTOMA; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INTESTINE PERFORATION; KIDNEY FAILURE; LEIOMYOSARCOMA; LIPOSARCOMA; MALE; MAXIMUM TOLERATED DOSE; MENORRHAGIA; MUCOSA INFLAMMATION; MYALGIA; NAIL DISEASE; NAUSEA; NECROTIZING PNEUMONIA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PERIVASCULAR EPITHELIOID CELL TUMOR; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEINURIA; RECURRENT CANCER; RIGOR; RISK BENEFIT ANALYSIS; SARCOMA; SENSORY NEUROPATHY; SOFT TISSUE SARCOMA; STOMATITIS; SYNOVIAL SARCOMA; TISSUE LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WOUND DEHISCENCE;

EID: 84863238741     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr299     Document Type: Article

References (40)

1. Kostler WJ, Brodowicz T, Attems Y et al. Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. Ann Oncol 2001; 12: 1281-1288.
2. van Hoesel QG, Verweij J, Catimel G et al. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 1994; 5: 539-542.
3. Verweij J, Lee SM, Ruka W et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 2000; 18: 2081-2086.
4. Svancarova L, Blay JY, Judson IR et al. Gemcitabine in advanced adult softtissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38: 556-559.
5. Okuno S, Ryan LM, Edmonson JH et al. Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer 2003; 97: 1969-1973.
6. Okuno S, Edmonson J, Mahoney M et al. Phase II trial of gemcitabine in advanced sarcomas. Cancer 2002; 94: 3225-3229.
7. Hartmann JT, Oechsle K, Huober J et al. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs 2006; 24: 249-253.
8. Amodio A, Carpano S, Manfredi C et al. Gemcitabine in advanced stage soft tissue sarcoma: a phase II study. Clin Ter 1999; 150: 17-20.
9. Spath-Schwalbe E, Genvresse I, Koschuth A et al. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs 2000; 11: 325-329.
10. Hensley ML, Maki R, Venkatraman E et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002; 20: 2824-2831.
11. Bay JO, Ray-Coquard I, Fayette J et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer 2006; 119: 706-711.
12. Maki RG, Wathen JK, Patel SR et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007; 25: 2755-2763.
13. Vecchiarelli-Federico LM, Cervi D, Haeri M et al. Vascular endothelial growth factor-a positive and negative regulator of tumor growth. Cancer Res 2010; 70: 863-867.
14. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005; 3 (69 Suppl): 11-16.
15. Potti A, Ganti AK, Tendulkar K et al. Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. J Cancer Res Clin Oncol 2004; 130: 52-56.
16. Yudoh K, Kanamori M, Ohmori K et al. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer 2001; 84: 1610-1615.
17. Chao C, Al-Saleem T, Brooks JJ et al. Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann Surg Oncol 2001; 8: 260-267.
18. D'Adamo DR, Anderson SE, Albritton K et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005; 23: 7135-7142.
19. Park MS, Patel SR, Ludwig JA et al. Combination therapy with temozolomide and bevacizumab in the treatment of hemangiopericytoma/malignant solitary fibrous tumor. J Clin Oncol 2008; 26(Suppl): 10512.
20. Hormbrey E, Gillespie P, Turner K et al. A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful? Clin Exp Metastasis 2002; 19: 651-663.
21. Kut C, Mac Gabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 2007; 97: 978-985.
22. Edmonson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11: 1269-1275.
23. Toma S, Palumbo R, Sogno G et al. Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas. Ann Oncol 1992; 2 (3 Suppl): S119-S123.
24. Van Glabbeke M, van Oosterom AT, Oosterhuis JW et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999; 17: 150-157.
25. Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003; CD003293 doi:10.1002/ 14651858.
26. Nagano T, Yamada Y, Ikeda T et al. Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients. Cancer 2007; 110: 648-651.
27. Lahat G, Dhuka AR, Lahat S et al. Outcome of locally recurrent and metastatic angiosarcoma. Ann Surg Oncol 2009; 16: 2502-2509.
28. Penel N, Bui BN, Bay JO et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008; 26: 5269-5274.
29. Schlemmer M, Reichardt P, Verweij J et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2008; 44: 2433-2436.
30. Fury MG, Antonescu CR, Van Zee KJ et al. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 2005; 11: 241-247.
31. Koontz BF, Miles EF, Rubio MA et al. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. Head Neck 2008; 30: 262-266.
32. Maki RG, D'Adamo DR, Keohan ML et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27: 3133-3140.
33. Stuttfeld E, Ballmer-Hofer K. Structure and function of VEGF receptors. IUBMB Life 2009; 61: 915-922.
34. Hayes AJ, Mostyn-Jones A, Koban MU et al. Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br J Surg 2004; 91: 242-247.
35. Vigil CE, Chiappori AA, William CA et al. Phase II study of sunitinib malate (SM) in subjects with metastatic and/or surgically unresectable non-GIST soft tissue sarcomas. 2008; 26(Suppl): 10535.
36. Hensley ML, Sill MW, Scribner DR Jr. et al. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol 2009; 115: 460-465.
37. George S, Merriam P, Maki RG et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009; 27: 3154-3160.
38. Sleijfer S, Ray-Coquard I, Papai Z et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009; 27: 3126-3132.
39. Heymach JV, Desai J, Manola J et al. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 2004; 10: 5732-5740.
40. Baker LH, Rowinsky EK, Mendelson D et al. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol 2008; 26(Suppl): 5583-5588.